Use of prostaglandin e2 (pge2)-primed mesenchymal stem cell (msc) product in preparation of drug for treating lung injury (li)

Abstract

The present disclosure relates to the technical field of medicine, in particular to use of a prostaglandin E2 (PGE2)-primed mesenchymal stem cell (MSC) product in preparation of a drug for treating lung injury (LI). A preparation method of the PGE2-primed MSC product includes conducting mixed culture on PGE2 and MSCs to obtain the PGE2-primed MSC product. The PGE2 and the MSCs are subjected to the mixed culture to enhance functions of the MSCs, promote migration of the MSCs to injury sites, strengthen anti-inflammatory effects of the MSCs, facilitate MSC proliferation, effectively relieve various lung injuries, and accelerate regeneration of injured alveolar epithelial cells. The drug prepared from the PGE2-primed MSC product provided by the present disclosure can effectively relieve LI and accelerate the regeneration of injured alveolar epithelial cells, and a remarkable treatment effect is obtained.

Dependencies are inferred from the claim text.